News | Heart Failure | March 12, 2019

William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

Responsibilities will include supporting recently-launched 500-patient RELIEVE-HF pivotal study

William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

March 12, 2019 — V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief medical officer. Abraham makes this move to V-Wave after more than 16 years as director of the Division of Cardiovascular Medicine at the Ohio State University.

V-Wave is an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH).

Abraham has vast clinical trial experience with drugs and devices for heart failure. He has participated as a site principal investigator (PI) in more than 100 multicenter clinical drug and device trials, serving as national or international PI and/or on the executive or steering committees of more than 50 multicenter trials. He was the lead author on the landmark MIRACLE clinical trial for cardiac resynchronization therapy published in 2002, a lead PI for the CHAMPION implantable hemodynamic monitoring trial published in 2011, and one of the lead PIs for the recently published COAPT trial studying percutaneous mitral valve repair. He has participated in all regulatory phases of new device development from pre-clinical assessment through U.S. Food and Drug Administration (FDA) pre-market approval (PMA) submission and approval. He has authored more than 1,000 original research manuscripts and other papers, and has been published in high impact journals, including The New England Journal of Medicine, The Lancet and the Journal of the American Medical Association.

Watch the VIDEO: MitraClip to Treat Heart Failure - Results of the COAPT Trial, an interview with Abraham at TCT 2018

V-Wave CEO Neal Eigler, M.D., said that among Abraham’s duties will be supporting the recently launched 500-patient RELIEVE-HF pivotal study.

"I loved my leadership roles at Ohio State," noted Abraham. "Given the enormous potential impact of the V-Wave product, I am delighted that the next stage of my career will be focused on bringing the interatrial shunt to millions of patients worldwide. Advanced HF is a major public health problem in the U.S. and around the world, with more than 6 million Americans suffering from the condition. For decades, we have been managing severe heart failure, both preserved and reduced ejection fraction, using diuretics to modify total blood volume in order to control cardiac pressures. Interatrial shunting could supplement current therapies by providing a novel therapeutic approach that specifically regulates cardiac pressures and volumes. The V-Wave approach is physiologically validated and self-regulating, meaning that as left atrial pressure rises, the amount of shunting increases and this shift of volume from left to right atrium then lowers left atrial pressure, with the intent of improving patient symptoms and clinical outcomes."

Abraham earned his medical degree from Harvard Medical School and completed his residency in internal medicine and fellowships in cardiology and heart failure/cardiac transplantation at the University of Colorado Health Sciences Center. Previously at The Ohio State University, Abraham also served as deputy director of Ohio State's Dorothy M. Davis Heart and Lung Research Institute, associate dean for clinical research, and medical director of the Clinical Trials Management Office at the Medical Center. While stepping down from his division director and other leadership positions, Abraham will maintain his academic title as professor of internal medicine, physiology and cell biology, so he may continue to participate in patient care and scholarly activities at the university.

Watch the VIDEO: Technologies to Reduce Heart Failure Readmissions, an interview with Abraham at TCT 2016.

For more information:

Related Heart Failure Content

VIDEO: Vest May Help Reduce Heart Failure Readmissions

VIDEO: Therapies for Advanced Heart Failure

Related Content

Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is a walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Overlay Init